Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Polycystic Ovary Syndrome (PCOS)Obstructive Sleep ApneaObesity
Interventions
DRUG

Progesterone

Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.

DRUG

testosterone

Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.

DRUG

glucocorticoid

Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.

DEVICE

continuous positive airway pressure

Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.

DRUG

Estrogen

Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.

OTHER

Control

No treatment with studies performed 31 to 72 days apart

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT00805207 - Sex Steroids, Sleep, and Metabolic Dysfunction in Women | Biotech Hunter | Biotech Hunter